Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT07511543

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07511543
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07511543. Randomized; single masking; primary purpose treatment. Start 2026-10-31 (anticipated); primary completion 2028-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
Acronym
LEAST
Intervention (Drug)
Semaglutide
Lead sponsor
Population Health Research Institute (class: other)

Record details

Record id
cardio:ct-nct07511543
Content hash
04c6500cb0090469981a002f13a55d8aac76762837406cf40789809fe9a59f74